Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Amazon.com, Inc. (AMZN) -- Ignore unavailable to you. Want to Upgrade?

To: Skeeter Bug who wrote (129282)	7/28/2001 5:51:59 PM
From: H James Morris	Respond to of 164684

What's wrong with vertical? Btw Icos IPO'd at 8. If you don't trust me on that then just ask Bill Gates.:O) siliconinvestor.com >SEATTLE _ Bothell-based Icos reported increased revenue, a narrower loss and progress on its products in addition to Cialis, its looming challenger to Viagra in treatment of impotence. The biotechnology company reported a second-quarter loss of $5.3 million, or 10 cents a share, down 36.2 percent from a loss of $8.3 million, or 18 cents a share, in the same quarter a year ago. Its revenue for the quarter ended June 30 was up 73.2 percent to $34 million from $19.6 million, boosted by a $15 million licensing fee it received from Eli Lilly for filing its Cialis application with the Food and Drug Administration (FDA). It was a busy quarter for Icos. In the last three months, the company filed its first application with the FDA and with European regulators. Icos also is bracing for a marketing war with Pfizer's Viagra, and it has enrolled patients in clinical trials for Pafase, its treatment for severe sepsis, and for sitaxsentan, its treatment for pulmonary hypertension.